IBIO
Price
$0.98
Change
+$0.05 (+5.38%)
Updated
Jun 6 closing price
Capitalization
15.31M
ORYZF
Price
$3.03
Change
-$0.00 (-0.00%)
Updated
Jun 3 closing price
Capitalization
255.76M
Interact to see
Advertisement

IBIO vs ORYZF

Header iconIBIO vs ORYZF Comparison
Open Charts IBIO vs ORYZFBanner chart's image
iBio
Price$0.98
Change+$0.05 (+5.38%)
Volume$463.74K
Capitalization15.31M
Oryzon Genomics SA
Price$3.03
Change-$0.00 (-0.00%)
Volume$2.28K
Capitalization255.76M
IBIO vs ORYZF Comparison Chart
Loading...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IBIO vs. ORYZF commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Buy and ORYZF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (IBIO: $0.81 vs. ORYZF: $3.03)
Brand notoriety: IBIO and ORYZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 12% vs. ORYZF: 58%
Market capitalization -- IBIO: $15.31M vs. ORYZF: $255.76M
IBIO [@Biotechnology] is valued at $15.31M. ORYZF’s [@Biotechnology] market capitalization is $255.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 1 FA rating(s) are green whileORYZF’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 1 green, 4 red.
  • ORYZF’s FA Score: 1 green, 4 red.
According to our system of comparison, ORYZF is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 5 TA indicator(s) are bullish.

  • IBIO’s TA Score: 5 bullish, 2 bearish.

Price Growth

IBIO (@Biotechnology) experienced а +4.62% price change this week, while ORYZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORYZF($256M) has a higher market cap than IBIO($15.3M). ORYZF YTD gains are higher at: 87.037 vs. IBIO (-67.102). ORYZF has higher annual earnings (EBITDA): 834K vs. IBIO (-12.84M). ORYZF has more cash in the bank: 8.44M vs. IBIO (7.02M). IBIO has higher revenues than ORYZF: IBIO (375K) vs ORYZF (0).
IBIOORYZFIBIO / ORYZF
Capitalization15.3M256M6%
EBITDA-12.84M834K-1,539%
Gain YTD-67.10287.037-77%
P/E Ratio0.65N/A-
Revenue375K0-
Total Cash7.02M8.44M83%
Total Debt4MN/A-
FUNDAMENTALS RATINGS
IBIO: Fundamental Ratings
IBIO
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IBIO
RSI
ODDS (%)
Bullish Trend 12 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
80%
Momentum
ODDS (%)
Bullish Trend 12 days ago
78%
MACD
ODDS (%)
Bullish Trend 12 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 27 days ago
80%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with REPL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
-0.32%
REPL - IBIO
38%
Loosely correlated
+0.12%
LIANY - IBIO
37%
Loosely correlated
N/A
NUVB - IBIO
36%
Loosely correlated
-1.79%
LENZ - IBIO
35%
Loosely correlated
-2.35%
STOK - IBIO
31%
Poorly correlated
+2.72%
More

ORYZF and

Correlation & Price change

A.I.dvisor tells us that ORYZF and REPL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORYZF and REPL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
N/A
REPL - ORYZF
30%
Poorly correlated
+0.12%
TVGN - ORYZF
24%
Poorly correlated
+1.55%
GNNSF - ORYZF
24%
Poorly correlated
N/A
IBIO - ORYZF
23%
Poorly correlated
-0.32%
BMRN - ORYZF
23%
Poorly correlated
-0.03%
More